Completed PHASE1 INTERVENTIONAL 3-arm NCT03289208

Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Renal Impairment

An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of MCI-186 in Subjects With Mild or Moderate Renal Impairment Compared to Subjects With Normal Renal Function

Sponsor: Tanabe Pharma Corporation

Conditions Healthy Renal Impairment

Interventions MCI-186

Updated 10 times since 2017 Last updated: Dec 15, 2025 Started: Oct 27, 2016 Primary completion: Apr 16, 2018 Completion: Apr 20, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03289208, this PHASE1 trial focuses on Healthy and Renal Impairment and remains completed. Sponsored by Tanabe Pharma Corporation, it has been updated 10 times since 2016, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

10 versions recorded

Feb 2026 — Present [monthly]

Completed PHASE1
Jan 2026 — Feb 2026 [monthly]

Completed PHASE1
Sep 2024 — Jan 2026 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
May 2023 — Jul 2024 [monthly]

Completed PHASE1

▶ Show 5 earlier versions

Jan 2021 — May 2023 [monthly]

Completed PHASE1
Mar 2020 — Jan 2021 [monthly]

Completed PHASE1
Jul 2018 — Mar 2020 [monthly]

Completed PHASE1

Status: Recruiting → Completed
Jun 2018 — Jul 2018 [monthly]

Recruiting PHASE1
Oct 2017 — Jun 2018 [monthly]

Recruiting PHASE1

First recorded

Oct 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Tanabe Pharma Corporation

Data source: Tanabe Pharma Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tokyo, Japan